RGDペプチド 2020/01/01
細胞外マトリックスタンパク質など、多くの細胞接着性タンパク質に共通で保 存されている、Arg-Gly-Asp配列(RGD配列)を有する製品のリストです。
| Code | Compound | |
|---|---|---|
| 4171 | Fibronectin Active Fragment (RGDS) | |
| 4171-v | Fibronectin Active Fragment (RGDS) | |
| 4189 | Fibronectin Active Fragment (GRGDS) | |
| 4189-v | Fibronectin Active Fragment (GRGDS) | |
| 4304 | cyclo(Arg-Gly-Asp-D-Phe-Val) | Angiogenesis Inhibitor |
| 4304-v | cyclo(Arg-Gly-Asp-D-Phe-Val) | Angiogenesis Inhibitor |
| CAN-3505-PI | H-[Lys-Leu-Ala-Lys-Leu-Ala-Lys]2-Gly-Phe-Leu-Gly-(Cys-Gln-Thr-Pro-Tyr-Tyr-Met-Asn-Thr-Cys)-OH | Cell Penetrating Peptide (CPP). Targets EGFR, Binding to a Specific Protein in Carcinoma Cells, and Induces Apoptosis. |
| ECT-3760-PI | Echistatin | αVß3 Integrin Antagonist |
| FAP-3758-PI | Fibronectin Adhesion-Promoting Peptide | |
| PCA-3618-PI | Cyclo(Arg-Ala-Asp-D-Phe-Val) | Negative Control for ICA-4304 |
| PCI-3651-PI | H-Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 | αvß3 Integrin Binding RGD Peptide; RGD Tumor Targeting Peptide (Requires further derivatization before use) |
| PCI-3661-PI | Cyclo(Arg-Gly-Asp-D-Phe-Lys) | αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide(Requires Further Derivatization Before Use) |
| PCI-3662-PI | Cyclo(Arg-Gly-Asp-D-Tyr-Lys) | αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting and Tumor Imaging Peptide (Requires Further Derivatization Before Use) |
| PCI-3686-PI | Cyclo(Arg-Gly-Asp-D-Phe-Cys) | RGD Tumor Targeting Peptide (linker additions via Cys) (May Require Further Derivatization Before Use) |
| PCI-3687-PI | Cyclo(Arg-Gly-Asp-D-Phe-Glu) | RGD Peptide for Radiolabeling and Imaging (Requires Further Derivatization Before Use) |
| PCI-3688-PI | Cyclo(Arg-Gly-Asp-D-Tyr-Glu) | RGD Peptide for Radiolabeling (Requires further derivatization before use) |
| PCI-3696-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG)] | RGD Peptide Equipped with PEG Spacers for More Efficient Binding to Lipid Surfaces(Requires Further Derivatization Before Use) |
| PCI-3697-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Biotin-PEG-PEG)] | RGD Peptide Equipped with a Biotin Reporting Tag and PEG Spacers for More Efficient Binding to Lipid Surfaces (Requires Further Derivatization Before Use) |
| PCI-3699-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Ac-SCH2CO)] | RGD Peptide Equipped with Thioacetyl Group for Linking to Liposomes (May Require Further Derivatization and Deprotection Before Use) |
| PCI-3790-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(dPEG®4)] | RGD Tumor Targeting (and With Radiolabeling, A Tumor Imaging Peptide) |
| PCI-3808-PI | Cyclo[Arg-Ala-Asp-D-Phe-Lys(Biotin-PEG-PEG)] | Negative Control Peptide for PCI-3697-PI |
| PCI-3823-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG-Cys)] | |
| PCI-3861-PI | Cyclo[Arg-Gly-Asp-D-Tyr-Lys(Cys-AEEA-DOTA)] | RGD Peptide Functionalized with a Radiometal Chelator, DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid); Potentially Useful for Tumor Targeting and Imaging. |
| PCI-3883-PI | Cyclo(Arg-Ala-Asp-D-Phe-Lys) | Negative Control RGD Peptide for PCI-3661-PI |
| PCI-3894-PI | Cyclo(Arg-Ala-Asp-D-Tyr-Lys) | Control Peptide of cyclo (Arg-Gly-Asp-D-Tyr-Lys) (PCI-3662-PI) |
| PCI-3895-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Biotin)] | RGD Peptide Equipped with a Biotin Reporting Tag |
| PCI-3898-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(H-Ser)] | αvß3 Integrin Binding RGD Peptide; RGD Tumor Targeting Peptide (Requires further derivatization before use) |
| PCI-3899-PI | H-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 | Tumor Targeting and Tumor Imaging Peptide (Requires Further Derivatization Before Use) |
| PCI-3903-PI | DOTA-Glu-[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 | αvß3 Integrin Binding RGD Peptide RGD Tumor Targeting Peptide for Radiolabelling (Requires further derivatization before use) |
| PCI-3904-PI | H-Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2 | RGD Tumor Targeting and Tumor Imaging Peptide (Requires further derivatization before use) |
| PCI-3909-PI | H-Gly-Arg-Gly-Asp-Asn-Pro-OH | RGD peptide and Inhibitor of Cell Adhesion to Fibronectin |
| PCI-3910-PI | H-Gly-Arg-Ala-Asp-Ser-Pro-OH | Negative Control for Fibronectin Inhibitors |
| PCI-3912-PI | Cyclo(Arg-Gly-Asp-D-Tyr-Cys) | |
| PCI-3917-PI | Cyclo(Arg-Ala-Asp-D-Tyr-Cys) | |
| PCI-3919-PI | Cyclo(Arg-Gly-Asp-D-Phe-Lys) | RGD Tumor Targeting Peptide (Requires further derivatization before use) |
| PCI-3929-PI | H-Arg-Gly-Asp-Ser-Lys-OH | RGD Tumor-Targeting Peptide |
| PCI-3930-PI | H-Arg-Ala-Asp-Ser-Lys-OH | Negative Control for PLI-3929-PI |
| PCI-3953-PI | Cyclo(Arg-Gly-Glu-D-Phe-Lys) | |
| PCI-3954-PI | Cyclo[Arg-Ala-Asp-D-Phe-Lys(PEG-PEG)] | Negative Control Peptide for PCI-3696-PI |
| PCI-3959-PI | Cyclo[Arg-Ala-Asp-D-Phe-Lys(Ac-SCH2CO)] | Control for PCI-3699-PI |
| PCI-3960-PI | Cyclo(Arg-Ala-Asp-D-Phe-Cys) | Negative Control Peptide for PCI-3686-PI |
| PCI-3963-PI | H-Pro-His-Ser-Arg-Asn-OH | |
| PCI-3964-PI | H-Gly-Asp-Gly-Val-D-Ile-Thr-Arg-Ile-Arg-OH | CD36 Binding Peptide |
| PCI-3965-PI | H-Gly-Gly-Gly-Gly-Arg-Gly-Asp-Ser-Pro-OH | |
| PCI-3975-PI | H-Glu{Glu[Cyclo(Arg-Gly-Asp-D-Phe-Lys)]2}2 | Tetrameric RGD Peptide |
| PCI-3977-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-COCH2CH2SH)] | |
| PCI-3979-PI | H-Glu[Cyclo(Arg-Ala-Asp-D-Phe-Lys)]2 | Negative Control Peptide for PCI-3651-PI |
| PFA-3907-PI | H-Gly-Arg-Gly-Glu-Ser-OH | Negative Control for 4189-v |
| PFA-3924-PI | Ac-Gly-D-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-(Gly)4-Ser-D-Arg-(Leu)6-D-Arg-NH2 | Hydrophobic RGD Fibronectin Peptide |
| RGD-3000-PI | Cyclo[Arg-Gly-Asp-D-Tyr-Lys(PEG)] | |
| RGD-3005-PI | Cyclo[Arg-Ala-Asp-D-Tyr-Lys(PEG)] | Control peptide for RGD-3000-PI |
| RGD-3035-PI | Ac-cyclo [Pen-Tyr(Me)-Ala-Arg-Gly-Asp-Asn-Tic-Cys]-NH2 | Cell Penetrating Peptide That Targets EGFR, Binds to a Specific Protein in Carcinoma Cells, and Induces Apoptosis |
| RGD-3506-PI | H-Gly-Arg-Gly-Asp-Ser-Pro-Cys-OH | Thiolated Cell Adhesion Peptide |
| RGD-3736-PI | Galactosyl-Cyclo(Arg-Gly-Asp-D-Phe-Lys) | Glycosylated RGD for Radiolabelling |
| RGD-3749-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] | Clickable RGD for Dendrimer Constructs |
| RGD-3750-PI | H-dPEG®4-Glu[dPEG®4(Cyclo(Arg-Gly-Asp-d-Phe-Lys))]2 | For In Vitro Assays of Integrin αvß3/αvß5 Expression in Tumor Tissues |
| RGD-3759-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG-PEG-Azide)] | Clickable RGD for Dendrimer Constructs |
| RGD-3761-PI | H-[Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys]-NH2 | RGD Tumor Targeting Peptide |
| RGD-3762-PI | H-[Cys-Arg-Gly-Asp-Arg-Gly-Pro-Asp-Cys]-NH2 | RGD Tumor Targeting Peptide |
| RGD-3766-PI | H-AEEEA-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 | Bicyclic RGD Peptide for Imaging |
| RGD-3782-PI | Galacto-RGD2 | Ddimer |
| RGD-3794-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Cys)] | RGD Peptide for Radiolabeling and Imaging |
| RGD-3795-PI | Cyclo[Arg-Gly-Asp-D-Phe-Lys(Mal)] | RGD Peptide With 3-Maleimidopropionic Acid Functional Group |
| RGD-3842-PI | Cyclo[Arg-Ala-Asp-D-Phe-Lys(Azide)] | Negative Control Peptide for RGD-3749-PI |
| RGD-3879-PI | N3-PEG-PEG3-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 | Bicyclic RGD peptide Optimized for Click Chemistry |
| RGD-3993-PI | Mal-PEG3-Glu[Cyclo(Arg-Gly-Asp-D-Tyr-Lys)]2 | Dimeric RGD peptide for click chemistry |
